

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

213801Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION

CLINICAL STUDIES

NDA Serial Number: 213801

Drug Name: Myrbetriq Granules (Mirabegron for extended release oral suspension)

Indication(s): Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older

Applicant: Astellas Pharma Global Development, INC.

Date(s): Receipt Date: 09/28/2020
PDUFA Date: 03/28/2021

Review Priority: Priority

Biometrics Division: Division of Biometrics IV

Statistical Reviewer: Jia Guo, Ph.D.

Concurring Reviewers: Daphne Lin, Ph.D. Acting Team Leader, Deputy Director

Medical Division: Division of Urology, Obstetrics and Gynecology (DUOG)

Clinical Team: Elena Boley, M.D., Clinical Reviewer
Mark Hirsch, M.D., Clinical Team Leader

Project Manager: Nenita Crisostomo

Keywords: Change from Baseline

Table of Contents

1	EXECUTIVE SUMMARY	4
2	INTRODUCTION	5
2.1	OVERVIEW.....	5
2.2	DATA SOURCES	5
3	STATISTICAL EVALUATION	6
3.1	DATA AND ANALYSIS QUALITY	6
3.2	EVALUATION OF EFFICACY	6
3.2.1	<i>Study Design and Endpoints</i>	6
3.2.2	<i>Statistical Methodologies</i>	7
3.2.3	<i>Subject Disposition, Demographic and Baseline Characteristics</i>	8
3.2.4	<i>Results and Conclusions</i>	8
3.3	EVALUATION OF SAFETY	11
4	FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	11
4.1	GENDER, RACE, AGE, AND GEOGRAPHIC REGION	11
4.2	OTHER SPECIAL/SUBGROUP POPULATIONS	13
5	SUMMARY AND CONCLUSIONS	13
5.1	STATISTICAL ISSUES AND COLLECTIVE EVIDENCE	13
5.2	CONCLUSIONS AND RECOMMENDATIONS	13
6	APPENDICES.....	14

LIST OF TABLES

Table 1: List of all Studies included in the Statistical Review	5
Table 2: Summary of Subject Disposition and Analysis Sets	8
Table 3: Change from Baseline in Maximum Cystometric Capacity (mL) (FAS)	9
Table 4: Change from Baseline to Week 24 in Bladder Compliance (mL/cm H ₂ O) (FAS)	9
Table 5: Change from Baseline to Week 24 in Number of Overactive Detrusor Contractions (> 15 cm H ₂ O) Until End of Bladder-filling (FAS)	9
Table 6: Change from Baseline to Week 24 in Bladder Volume until First Detrusor Contraction > 15 cm H ₂ O	10
Table 7: Change from Baseline to Week 24 in Maximum Catheterized Daytime Volume (mL) (FAS)	10
Table 8: Change from Baseline to Week 24 in Mean Number of Leakage Episodes per 24 Hours (FAS)	11
Table 9: Subgroup Analysis of Change from Baseline to Week 24 (LOCF) in Maximum Cystometric Capacity (mL) by Gender (FAS)	12
Table 10: Change from Baseline to Week 24 in Maximum Cystometric Capacity (mL) at Week 24 (LOCF)	12
Table 11: Summary of Demographics and Baseline Characteristics (SAF)	14

1 EXECUTIVE SUMMARY

Myrbetriq® 25 mg and 50 mg tablets (Mirabegron) is currently approved under NDA 202611 for treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. A Written Request (WR) for the use of mirabegron in treatment of neurogenic detrusor overactivity (NDO) in pediatric patients was issued under NDA 202611 on 18 March 2016.

In this submission, the Applicant submitted the safety and efficacy data from one study to fulfill the WR and seek approval of mirabegron for NDO in pediatric patients. This review is to evaluate from a statistical perspective if the submitted information supports this claim.

The study was a multinational, multi-center, open-label, single arm phase 3 study with a 12-week dose titration period followed by 40 weeks of treatment with fixed dose in subjects between 3 to 18 years old.

The primary efficacy endpoint was the change from baseline in maximum cystometric capacity (MCC) during treatment period at week 24 (measured in mL). It was summarized using descriptive statistics and the mean change from baseline estimate, together with 95% CI. The lower bound of the two-sided 95% CI was assessed to see if it excluded 0. Due to lack of a control group, the interpretation of the results is descriptive in nature. Secondary efficacy endpoints based on urodynamics and patient diary were also evaluated in a similar way as the primary efficacy endpoint.

In children (3-12 years old), the MCC was increased by 72.1 mL (SD: 87.1, 95% CI 45.3 to 98.9); in adolescents (12-18 years old), the MCC was increased by 113.2 mL (SD: 83.0, 95% CI 79.0 to 147.5);

The study demonstrated that there is clinical benefit of mirabegron in treatment of NDO in pediatric subjects.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.